AGM
MRTX

Alpine Global Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Alpine Global Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-15,062
Closed -$2.21M – 778
2021
Q4 		$2.21M Buy
+15,062
New +$2.34M 0.32% 62
2021
Q2 		– Sell
-2,675
Closed -$458K – 390
2021
Q1 		$458K Buy
+2,675
New +$530K 0.04% 174
2018
Q1 		– Sell
-18,472
Closed -$337K – 205
2017
Q4 		$337K Buy
+18,472
New +$287K 0.08% 99

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Alpine Global Management's MRTX Position: Q1 2022 in Review

Alpine Global Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2022, closing a stake of 15,062 shares — an estimated $2.21M sold.

Alpine Global Management first reported a position in MRTX in Q4 2017 and held it in 3 quarters. The position peaked at $2.21M in Q4 2021. 253 funds tracked by Wall St. Rank hold MRTX as of Q1 2022.

  • Alpine Global Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Alpine Global Management sold 15,062 Mirati Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $2.21M.
  • Alpine Global Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2017 and held it in 3 quarters.
  • Alpine Global Management's Mirati Therapeutics, Inc. Common Stock position peaked at $2.21M in Q4 2021.
  • 253 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Alpine Global Management's 13F filing for Q1 2022, filed 13 May 2022.